Sign in
CompletedNo phase

Clinical Decision Support Tool for Vancomycin Dosing in Children

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
People taking part
75 people enrolled
Started
9 May 2022
Ended
10 May 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Computer Decision Support Tool Intervention Group
  • Matched Historical Controls
Record updated
14 May 2025

Who can take part

Age
Up to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Hospitalized infants and children from postmenstrual age of 38 weeks to age 19 years Requiring IV vancomycin, regardless of indication
  • Parent or legally authorized representative is willing to provide permission and sign the informed consent document; subjects assent, when appropriate
  • Hospitalized neonates, infants, children, adolescents who require, but have not been initiated on intravenous vancomycin therapy

Who cannot take part

  • Patients who had received vancomycin during previous 2 weeks
  • Patients with end-stage renal disease, receiving hemodialysis or receiving continuous renal replacement therapy
  • Receiving extracorporeal therapy, including extracorporeal membrane oxygenation, continuous renal replacement therapy, and extracorporeal liver support
  • On oral or intraperitoneal vancomycin
  • Will only receive a single dose of vancomycin
  • Known to be pregnant
  • Is brain dead or has suspected brain death

Where in United States

  • University of Maryland Medical CenterBaltimore, United States

About the trial

What the trial wants to find out

This study will evaluate the pharmacokinetic and pharmacodynamic dosing properties of intravenous vancomycin in pediatric patients using a novel computer decision support (CDS) tool called Lyv. Dosing will be individualized based on AUC24/MIC. The results will be compared to matched historical controls.

The 2 groups in the trial

  • Intervention Group- Computer Decision Support ToolTreatment being tested

    Patients enrolled in the study will be started on IV vancomycin which will be dosed based on the LYV CDS tool, which will dose patients based on AUC24/MIC. Dosing will be adjusted based on vancomycin levels that will be drawn throughout the hospital stay. All patients prospectively enrolled into this study will be in the intervention group. Results will be compared to the retrospectively matched historical controls.

    Treatment: Computer Decision Support Tool Intervention Group

  • Matched Historical ControlsOther group

    Match historical controls are patients that were on IV vancomycin with dose adjustments based on vancomycin trough levels. Patients in this study arm will be retrospective patients that will be matched with the intervention group.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pharmacokinetic Study to Evaluate the Use of a Novel Clinical Decision Support Tool, Lyv, in Achieving AUC24/MIC > 400 in Pediatric Patients on Vancomycin
Record updated
14 May 2025